Schering-Plough, Merck's Vytorin misses study goal
Monday, July 21, 2008 - 16:07
in Health & Medicine
TRENTON, N.J. (AP) -- In the latest disappointment for cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease or lower the need for valve surgery, sending its makers' stock plunging....